MLYS vs REGN: Which Stock is Better?
Side-by-side comparison of Mineralys Therapeutics, Inc. Common Stock and Regeneron Pharmaceuticals Inc in 2026
MLYS
Mineralys Therapeutics, Inc. Common Stock
$31.93
REGN
Regeneron Pharmaceuticals Inc
$733.78
Key Metrics Comparison
| Metric | MLYS | REGN | Winner |
|---|---|---|---|
| Market Cap | $2.59B | $77.77B | REGN |
| P/E Ratio | N/A | 17.58 | REGN |
| EPS (TTM) | $N/A | $41.75 | REGN |
| Revenue Growth | 0.0% | 0.0% | REGN |
| Gross Margin | 0.0% | 45.8% | REGN |
Analyze MLYS
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is MLYS or REGN a better investment?
Comparing MLYS and REGN: Mineralys Therapeutics, Inc. Common Stock has a market cap of $2.59B while Regeneron Pharmaceuticals Inc has $77.77B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between MLYS and REGN?
MLYS (Mineralys Therapeutics, Inc. Common Stock) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: MLYS or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: MLYS or REGN?
REGN has higher revenue growth at 0.0% vs 0.0% for MLYS.
Which company is more profitable: MLYS or REGN?
Regeneron Pharmaceuticals Inc (REGN) has higher gross margins at 45.8% compared to 0.0% for MLYS.
Which is the larger company: MLYS or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $77.77B compared to $2.59B for MLYS.
Should I buy MLYS or REGN in 2026?
Both MLYS and REGN have investment merit. MLYS trades at $31.93 while REGN trades at $733.78. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between MLYS and REGN stock?
Key differences: Market Cap ($2.59B vs $77.77B), P/E Ratio (N/A vs 17.6x), Revenue Growth (0.0% vs 0.0%), Gross Margin (0.0% vs 45.8%).